Amendments to the America Invents Act passed

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Amendments to the America Invents Act passed

A bill designed to solve problems in the new US patent system has been passed by Congress after being amended to remove some contentious clauses

It follows a ruling by the Federal Circuit on Thursday that affirmed parts of the America Invents Act (AIA) that prevent qui tam lawsuits being filed against false patent claims. The two developments together will change patent law in the US dramatically, attorneys say.

The bill, HR 6621, was proposed by Representative Lamar Smith and aimed to improve several provisions of the AIA. It was passed by 308-89 votes. In order for it to become law, the Senate will also have to affirm it.

Originally, the bill included a controversial provision which would have cut short the length of patents issued before the General Agreement on Tariffs and Trade (GATT). Around 200 patents issued before June 1995, when GATT came in, are still being processed by the patent office.

Pre-GATT patents have a term of 17 years from the date of issuance, regardless of how long the patent is in prosecution. Patents filed after GATT have a term of 20 years from the earliest priority filing date. The proposed legislation would have denied the 17-year-from-grant term unless the patent was issued within one year of the legislation becoming effective.

The provision was designed to close a loophole in the law which creates the potential for so-called submarine patents.

With pre-GATT applications, patent applicants can repeatedly file for continuations to keep the patent in prosecution. This prevents the patent from being made public, so that competitors are unaware of what it covers. Once a competitor launches a similar product, the patent applicant can wait for the patent to be issued and sue for infringement.

Michael Samardzija, a partner of Bracewell & Giuliani, said the provision would have effectively meant that most pre-GATT applications would be expired the moment they were issued.

The controversial provision was later replaced by a requirement that the USPTO submits a report to the Committees on the Judiciary of the United States House of Representatives and the Senate on the status of pre-GATT patents.

It passed despite objections from Representative Dana Rohrabacher, who argued that the names of patent applicants have traditionally been kept confidential and revealing the names of inventors would expose them to "attack by very powerful interests who would steal their invention."

The bill was also amended to remove a clause which would have subjected reissue patents to post-grant review.

However, Samardzija said the bill failed to address one of inventors' biggest concerns – the transition to a first-inventor-to-file system.

"It's another way for a big corporation, if it wanted to, to act like a bully and try to negotiate a licence at a rate it likes or to try to kill the patent of a smaller company that's trying to compete with it. Even if it is not successful at killing the patent, the fact that it has spent so much money on it may prevent the smaller company from competing."

Samardzija suggested that in order to add some balance, the law should be changed so that companies challenging a patent via the USPTO lose the ability to launch litigation challenges to the same patent in future.

more from across site and SHARED ros bottom lb

More from across our site

Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Simon Wright explains why the UK should embrace the possibility of rejoining the UPC, and reveals how CIPA is reacting to this month’s historic Emotional Perception AI case at the UK Supreme Court
Matthew Grady of Wolf Greenfield says AI presents an opportunity in patent practice for stronger collaboration between in-house and outside counsel
Aparna Watal, head of trademarks at Halfords IP, discusses why lawyers must take a stand when advising clients and how she balances work, motherhood and mentoring
Discussion hosted by Bird & Bird partners also hears that UK courts’ desire to determine FRAND rates could see the jurisdiction penalised in a similar way to China
The platform’s proactive intellectual property enforcement helps brands spot and kill fakes, so they can focus on growth. Managing IP learns more about the programme
Hire of José María del Valle Escalante to lead the firm’s operations in ‘dynamic’ Catalonia and Aragon regions follows last month’s appointment of a new chief information officer
Gift this article